201 related articles for article (PubMed ID: 24906422)
1. Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
Schnell D; Buschke S; Fuchs H; Gansser D; Goeldner RG; Uttenreuther-Fischer M; Stopfer P; Wind S; Petersen-Sylla M; Halabi A; Koenen R
Cancer Chemother Pharmacol; 2014 Aug; 74(2):267-75. PubMed ID: 24906422
[TBL] [Abstract][Full Text] [Related]
2. Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study.
Wiebe S; Schnell D; Külzer R; Gansser D; Weber A; Wallenstein G; Halabi A; Conrad A; Wind S
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):461-469. PubMed ID: 27436099
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
[TBL] [Abstract][Full Text] [Related]
4. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K
Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
Zhao Q; Iyer GR; Verhaeghe T; Truyen L
J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of linagliptin in subjects with hepatic impairment.
Graefe-Mody U; Rose P; Retlich S; Ring A; Waldhauser L; Cinca R; Woerle HJ
Br J Clin Pharmacol; 2012 Jul; 74(1):75-85. PubMed ID: 22242621
[TBL] [Abstract][Full Text] [Related]
8. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
[TBL] [Abstract][Full Text] [Related]
9. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours.
Wind S; Schmid M; Erhardt J; Goeldner RG; Stopfer P
Clin Pharmacokinet; 2013 Dec; 52(12):1101-9. PubMed ID: 23813493
[TBL] [Abstract][Full Text] [Related]
11. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
Urva S; Quinlan T; Landry J; Ma X; Martin JA; Benson CT
Clin Pharmacokinet; 2022 Jul; 61(7):1057-1067. PubMed ID: 35674880
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
[TBL] [Abstract][Full Text] [Related]
13. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment.
Grasela DM; Christofalo B; Kollia GD; Duncan G; Noveck R; Manning JA; LaCreta FP
Pharmacotherapy; 2000 Jun; 20(6 Pt 2):87S-94S. PubMed ID: 10850525
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.
Kropeit D; McCormick D; Erb-Zohar K; Moiseev VS; Kobalava ZD; Stobernack HP; Zimmermann H; Rübsamen-Schaeff H
Br J Clin Pharmacol; 2017 Dec; 83(12):2678-2686. PubMed ID: 28722153
[TBL] [Abstract][Full Text] [Related]
16. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
[TBL] [Abstract][Full Text] [Related]
17. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
[TBL] [Abstract][Full Text] [Related]
18. A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment.
Taylor L; Crockett J; Tayo B; Morrison G
J Clin Pharmacol; 2019 Aug; 59(8):1110-1119. PubMed ID: 30921490
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment.
Sekar V; Spinosa-Guzman S; De Paepe E; Stevens T; Tomaka F; De Pauw M; Hoetelmans RM
Clin Pharmacokinet; 2010 May; 49(5):343-50. PubMed ID: 20384396
[TBL] [Abstract][Full Text] [Related]
20. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H
Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
